| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer
|
Yildiz, Ibrahim
|
|
2013
|
72 |
2 |
p. 437-444
|
artikel
|
| 2 |
A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis
|
Ikeda, Masafumi
|
|
2013
|
72 |
2 |
p. 463-470
|
artikel
|
| 3 |
A phase I, open-label, mass balance study of [14C] dacomitinib (PF-00299804) in healthy male volunteers
|
Bello, Carlo L.
|
|
2013
|
72 |
2 |
p. 379-385
|
artikel
|
| 4 |
A predictive pharmacokinetic–pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination
|
Terranova, Nadia
|
|
2013
|
72 |
2 |
p. 471-482
|
artikel
|
| 5 |
Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis
|
Peng, Zhi
|
|
2013
|
72 |
2 |
p. 305-314
|
artikel
|
| 6 |
Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments
|
Pauley, Jennifer L.
|
|
2013
|
72 |
2 |
p. 369-378
|
artikel
|
| 7 |
CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis
|
Zeng, Zhiyu
|
|
2013
|
72 |
2 |
p. 287-303
|
artikel
|
| 8 |
Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration–effect relationship support clinical dose and regimen selection
|
Xiang, Hong
|
|
2013
|
72 |
2 |
p. 405-415
|
artikel
|
| 9 |
DMET™ (Drug-Metabolizing Enzymes and Transporters) microarray analysis of colorectal cancer patients with severe 5-fluorouracil-induced toxicity
|
Rumiato, Enrica
|
|
2013
|
72 |
2 |
p. 483-488
|
artikel
|
| 10 |
Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
|
Tougeron, David
|
|
2013
|
72 |
2 |
p. 397-403
|
artikel
|
| 11 |
Erratum to: Differential toxicity biomarkers for irinotecan- and oxaliplatin- containing chemotherapy in colorectal cancer
|
Cortejoso, Lucía
|
|
2013
|
72 |
2 |
p. 491
|
artikel
|
| 12 |
Hepatic activation of irinotecan predicts tumour response in patients with colorectal liver metastases treated with DEBIRI: exploratory findings from a phase II study
|
Jones, R. P.
|
|
2013
|
72 |
2 |
p. 359-368
|
artikel
|
| 13 |
Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not)
|
Corsello, Salvatore Maria
|
|
2013
|
72 |
2 |
p. 489-490
|
artikel
|
| 14 |
Long-term efficacy of imatinib for treatment of metastatic GIST
|
Patel, Shreyaskumar
|
|
|
72 |
2 |
p. 277-286
|
artikel
|
| 15 |
Long-term efficacy of imatinib for treatment of metastatic GIST
|
Patel, Shreyaskumar
|
|
2013
|
72 |
2 |
p. 277-286
|
artikel
|
| 16 |
Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study
|
Karayama, Masato
|
|
2013
|
72 |
2 |
p. 445-452
|
artikel
|
| 17 |
Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy
|
Peng, Pei-Jian
|
|
2013
|
72 |
2 |
p. 323-328
|
artikel
|
| 18 |
Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer
|
Mansour, Maged
|
|
2013
|
72 |
2 |
p. 429-435
|
artikel
|
| 19 |
Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy
|
Chen, Cui
|
|
2013
|
72 |
2 |
p. 315-322
|
artikel
|
| 20 |
Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab
|
Hellmann, Matthew D.
|
|
2013
|
72 |
2 |
p. 453-461
|
artikel
|
| 21 |
Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study
|
Wolin, Edward M.
|
|
2013
|
72 |
2 |
p. 387-395
|
artikel
|
| 22 |
Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib
|
He, Peng
|
|
2013
|
72 |
2 |
p. 341-348
|
artikel
|
| 23 |
Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines
|
Sooman, Linda
|
|
2013
|
72 |
2 |
p. 329-340
|
artikel
|
| 24 |
The pharmacokinetics of letrozole in brain and brain tumor in rats with orthotopically implanted C6 glioma, assessed using intracerebral microdialysis
|
Dave, Nimita
|
|
2013
|
72 |
2 |
p. 349-357
|
artikel
|
| 25 |
Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate
|
Duncan, Ruth
|
|
2013
|
72 |
2 |
p. 417-427
|
artikel
|
Tijdschrift beschrijving